Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

H J DEEG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1184847469
CMS profile
326395
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,762.21

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $1,004.83 2
CSL Behring $757.38 8

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

H J DEEG

NPI 1184847469 · CMS profile ID 326395

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184847469?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
H J DEEG, NPI 1184847469, CMS profile ID 326395. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184847469?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). H J DEEG, NPI 1184847469, CMS profile ID 326395. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184847469?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
H J DEEG, NPI 1184847469, CMS profile ID 326395, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1184847469?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $1,762.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $1,000.0011/17/2023 Consulting Fee No dispute reported Delay: No
Change: CHANGED
06/30/2026 1049509047 CMS
CSL Behring $69.7911/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880663 CMS
CSL Behring $48.8510/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880657 CMS
CSL Behring $69.7910/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880653 CMS
CSL Behring $86.9710/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880635 CMS
CSL Behring $48.8509/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880623 CMS
CSL Behring $86.9709/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880629 CMS
CSL Behring $173.0808/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880611 CMS
CSL Behring $173.0807/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042880505 CMS
PFIZER INC. $4.8306/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049328183 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,800.31 12
PY2020 $12,698.75 15
PY2021 $24,374.27 15
PY2022 $5,814.00 5
PY2023 $1,762.21 10
PY2024 $733.40 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $4,801.26 7
PY2023 Principal investigator $237,389.68 20
PY2022 Principal investigator $123,016.79 20
PY2021 Principal investigator $95,992.72 26
PY2020 Principal investigator $1,761,459.14 87
PY2019 Principal investigator $534,218.82 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $33,364.66 12/08/2020 Covered Recipient Teaching Hospital
Duke Regional Hospital
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724387451
Principal investigator 1 CSL Behring $5,300.00 11/13/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395739
Principal investigator 1 CSL Behring $13,982.43 11/10/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395699
Principal investigator 1 CSL Behring $10,600.00 10/30/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395737
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $704.88 10/30/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031649
Principal investigator 1 CSL Behring $9,010.00 10/27/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395735
Principal investigator 1 CSL Behring $10,600.00 10/14/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395733
Principal investigator 1 CSL Behring $29,779.77 10/13/2020 Covered Recipient Teaching Hospital
Duke Regional Hospital
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724387437
Principal investigator 1 CSL Behring $14,840.00 10/06/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395731
Principal investigator 1 CSL Behring $9,088.00 09/30/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395697
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,990.42 09/24/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031547
Principal investigator 1 CSL Behring $25,440.00 09/21/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395727
Principal investigator 1 CSL Behring $243.84 09/18/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636338
Principal investigator 1 CSL Behring $81,770.72 09/15/2020 Covered Recipient Teaching Hospital
Duke Regional Hospital
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724387425
Principal investigator 1 CSL Behring $25,440.00 09/02/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395725
Principal investigator 1 CSL Behring $18,720.00 08/27/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395723
Principal investigator 1 CSL Behring $61,360.00 08/20/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395721
Principal investigator 1 CSL Behring $483.75 08/20/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395745
Principal investigator 1 CSL Behring $378.00 08/20/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395747
Principal investigator 1 CSL Behring $1,165.41 08/18/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636336
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $1,364.54 08/14/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031437
Principal investigator 1 CSL Behring $57,698.92 08/13/2020 Covered Recipient Teaching Hospital
Duke Regional Hospital
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724387361
Principal investigator 1 CSL Behring $62,400.00 08/12/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395719
Principal investigator 1 CSL Behring $54,080.00 08/07/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395717
Principal investigator 1 CSL Behring $118.00 08/07/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395753
Principal investigator 1 CSL Behring $322.50 08/07/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395755
Principal investigator 1 CSL Behring $39,520.00 08/06/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395715
Principal investigator 1 CSL Behring $36,400.00 07/28/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395713
Principal investigator 1 CSL Behring $177.00 07/27/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395741
Principal investigator 1 CSL Behring $322.50 07/27/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395743
Principal investigator 1 CSL Behring $73,840.00 07/23/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395711
Principal investigator 1 CSL Behring $91,520.00 07/22/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395709
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $4,247.71 07/16/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031317
Principal investigator 1 CSL Behring $6,279.18 07/09/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395635
Principal investigator 1 CSL Behring $17,585.95 07/09/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395637
Principal investigator 1 CSL Behring $180,960.00 07/09/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395707
Principal investigator 1 CSL Behring $53,040.00 07/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395705
Principal investigator 1 CSL Behring $20,280.00 07/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395729
Principal investigator 1 CSL Behring $177.00 07/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395751
Principal investigator 1 CSL Behring $806.25 07/03/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395749
Principal investigator 1 CSL Behring $164.18 07/01/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395757
Principal investigator 1 CSL Behring $195.91 07/01/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395759
Principal investigator 1 CSL Behring $99,840.00 06/30/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395665
Principal investigator 1 CSL Behring $611.45 06/25/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636334
Principal investigator 1 CSL Behring $20,800.00 06/11/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395663
Principal investigator 1 CSL Behring $20,280.00 06/11/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395667
Principal investigator 1 CSL Behring $22,880.00 06/10/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395661
Principal investigator 1 CSL Behring $13,864.36 06/09/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395633
Principal investigator 1 CSL Behring $164.18 06/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395693
Principal investigator 1 CSL Behring $195.91 06/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395695
Principal investigator 1 CSL Behring $37,440.00 05/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395659
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $32,374.00 05/07/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 (STANDARD DOSE) No dispute reported 06/30/2026 753031145
Principal investigator 1 CSL Behring $59.00 05/01/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395687
Principal investigator 1 CSL Behring $322.50 05/01/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395689
Principal investigator 1 CSL Behring $189.00 05/01/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395691
Principal investigator 1 Incyte Corporation $2,234.00 04/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF SWLA LLC
PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBROSIS (MF) OR HIGH RISK ESSENTIAL THROMBOCYTHEMIA (ET) OR ET PATIENTS RECEIVING ET DIRECTED THERAPY No dispute reported 06/30/2026 744303289
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $10,589.35 04/08/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753031045
Principal investigator 1 CSL Behring $39,032.41 04/07/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395631
Principal investigator 1 CSL Behring $21,840.00 04/07/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395657
Principal investigator 1 CSL Behring $36,400.00 03/24/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395655
Principal investigator 1 CSL Behring $1,124.36 03/24/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636332
Principal investigator 1 CSL Behring $1,016.59 03/23/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636330
Principal investigator 1 CSL Behring $4,203.52 03/19/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636328
Principal investigator 1 CSL Behring $62.34 03/17/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant No dispute reported 06/30/2026 724395629
Principal investigator 1 CSL Behring $59,280.00 03/17/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395653
Principal investigator 1 CSL Behring $118.00 03/17/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395673
Principal investigator 1 CSL Behring $322.50 03/17/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395675
Principal investigator 1 CSL Behring $20,800.00 03/16/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395651
Principal investigator 1 CSL Behring $12,648.15 03/12/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395627
Principal investigator 1 CSL Behring $8.00 03/12/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395681
Principal investigator 1 CSL Behring $118.00 03/12/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395683
Principal investigator 1 CSL Behring $322.50 03/12/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395685
Principal investigator 1 CSL Behring $49,920.00 03/11/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395649
Principal investigator 1 CSL Behring $27,040.00 03/05/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395647
Principal investigator 1 CSL Behring $619.05 03/05/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636326
Principal investigator 1 CSL Behring $908.25 02/20/2020 Non-covered Recipient Entity
Fred Hutchinson Cancer Research Center
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 764636324
Principal investigator 1 CSL Behring $39,520.00 02/19/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395645
Principal investigator 1 CSL Behring $161.25 02/18/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395669
Principal investigator 1 CSL Behring $189.00 02/18/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395671
Principal investigator 1 CSL Behring $18,720.00 02/13/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395643
Principal investigator 1 CSL Behring $59.00 02/10/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395677
Principal investigator 1 CSL Behring $161.25 02/10/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395679
Principal investigator 1 CSL Behring $1,749.01 02/06/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395625
Principal investigator 1 CSL Behring $31,200.00 01/29/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395641
Principal investigator 1 Celgene Corporation $1,466.64 01/27/2020 Non-covered Recipient Entity
Cancer Research Center
A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy & Safety Study of Fedratinib in Subjects w/ DIPSS-Intermediate or High-Risk PMF, post-PV MF, or post-ET MF & Previously Treated w/ Ruxolitinib incl. Sub-study w/ concomitant Luspatercept for anemia No dispute reported 06/30/2026 736451257
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $7,244.05 01/24/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSUS IV DECITABINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) No dispute reported 06/30/2026 753030867
Principal investigator 1 CSL Behring $67,600.00 01/21/2020 Non-covered Recipient Entity
FRED HUTCHINSON CANCER RESEARCH CENTER
A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study) No dispute reported 06/30/2026 724395639